Company profile: RareCyte
1.1 - Company Overview
Company description
- Provider of rare cell characterization and isolation solutions for life science research and diagnostic development, including the Orion Platform for whole slide multimodal imaging in spatial biology and biomarker quantitation; CyteFinder II for high-speed imaging with multiplexed liquid biopsy and tissue spatial analysis and single-cell or tissue micro-region retrieval; AccuCyte for isolating circulating tumor cells; Precision Biology Services; and customizable Orion biomarker panels for FFPE or frozen tissue.
Products and services
- AccuCyte: A blood-based process that isolates circulating tumor cells (CTCs) from blood, delivering reliable, accurate data for cancer diagnostics
- CyteFinder II Instrument: A high-speed, whole slide imaging system enabling multiplexed liquid biopsy and tissue spatial analysis, including single cell or tissue micro-region retrieval
- Orion Platform: A benchtop, high-resolution, whole slide multimodal imaging instrument engineered for spatial biology studies and biomarker quantitation.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to RareCyte
Identigen
HQ: Ireland
Website
- Description: Provider of DNA-based solutions to the agri-food industry, applying genetic identification to improve the quality, integrity and safety of the global food supply. Offers DNA TRACEBACK for verifying food origin and production practices, and DATALIVE for animal lifecycle insights to support sustainable business and environmental practices. Operates in Ireland, UK, EU, USA and Canada.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Identigen company profile →
RNAissance Ag
HQ: United States
Website
- Description: Provider of ribonucleic acid and RNAi products, offering innovative technology for large-scale fermentation-based production of exogenous RNAi, addressing mass production challenges and enabling farmers to protect and improve crops and cattle.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RNAissance Ag company profile →
OPX Biotechnologies
HQ: United States
Website
- Description: Provider of bioengineering technology to convert renewable feedstocks into biofuels and green chemistry products, leveraging its proprietary OPX EDGE (Efficiency Directed Genome Engineering) platform for rapid, rational, and robust optimization of microbes and bioprocesses; Colorado-based.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OPX Biotechnologies company profile →
Genomic Vision
HQ: France
Website
- Description: Provider of novel genetic tests and research tools for life sciences, developed and commercialized using Molecular Combing, a proprietary single DNA molecule detection technology, combined with biomarker discovery; focused on DNA analysis and genetic testing in cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genomic Vision company profile →
Devyser
HQ: Sweden
Website
- Description: Provider of diagnostic kits for complex DNA testing in oncology, hereditary diseases, and transplantation, used to guide targeted cancer therapies and enable genetic testing. Sold in 60+ countries, offerings include NGS-based tests for thalassemia, cystic fibrosis, familial hypercholesterolemia, thrombophilia, HFE mutations, and Y-chromosome microdeletions linked to male infertility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Devyser company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for RareCyte
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to RareCyte
2.2 - Growth funds investing in similar companies to RareCyte
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for RareCyte
4.2 - Public trading comparable groups for RareCyte
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →